Développement d'antimicrobiens à large spectre, inhibiteurs des enzymes impliquées dans la biosynthèse des lipides membranaires. // Development of broad-spectrum antimicrobials that inhibit enzymes involved in membrane lipid biosynthesis.
ABG-129235
ADUM-62836 |
Thesis topic | |
2025-03-07 | Public funding alone (i.e. government, region, European, international organization research grant) |
Université de Picardie - Jules Verne
Amiens - France
Développement d'antimicrobiens à large spectre, inhibiteurs des enzymes impliquées dans la biosynthèse des lipides membranaires. // Development of broad-spectrum antimicrobials that inhibit enzymes involved in membrane lipid biosynthesis.
- Chemistry
Antimicrobiens à large spectre, Chimie hétérocyclique, Inhibiteurs enzymatiques, Lipides membranaires
Broad-spectrum antimicrobials, Heterocyclic chemistry, Enzymatic inhibitors, Membrane lipids
Broad-spectrum antimicrobials, Heterocyclic chemistry, Enzymatic inhibitors, Membrane lipids
Topic description
Le développement de la résistance aux antibiotiques et aux antiparasitaires constitue un véritable enjeu de santé publique. Selon l'Organisation mondiale de la santé, la multi-résistance concerne à l'heure actuelle de nombreuses bactéries dont Pseudomonas aeruginosa, Acinetobacter baumannii ou des entérobactéries impliquées dans les infections nosocomiales. Ce phénomène de résistance est retrouvé chez des parasites tels que le P. falciparum, l'espèce la plus virulente de paludisme. Ainsi, il y a urgence à développer de nouveaux traitements efficaces visant de nouveaux processus biologiques vitaux non ciblés par les agents anti-infectieux actuels pour éviter les résistances croisées. Une voie thérapeutique prometteuse consiste à bloquer le fonctionnement des enzymes qui contrôlent le métabolisme des lipides membranaires, indispensable à l'intégrité de la cellule. FabZ et FabI, deux enzymes essentielles impliquées dans la biosynthèse de ces lipides, sont absentes chez l'homme mais présentes chez la plupart des bactéries et à P. falciparum. Ainsi, leurs inhibitions sélectives offrent l'opportunité de développer un antimicrobien à large spectre avec des effets indésirables limités. Dans le cadre de ce projet, nous nous focaliserons sur la synthèse et l'étude d'inhibiteurs de FabZ et de FabI. Ces travaux seront menés conjointement par cinq équipes de recherche. Cette collaboration pluridisciplinaire en chimie et en biologie devrait nous permettre, à l'issue de ce projet, de réunir un maximum de données afin de proposer rapidement un nouveau candidat médicament à large spectre antimicrobien.
La plus grande partie du travail de thèse du (de la) doctorant-e visera à la synthèse et l'étude des inhibiteurs des enzymes visées et la mesure in silico de leurs propriétés physico-chimiques. Il (elle) interviendra également dans les mesures de cytotoxicité et l'évaluation antibactérienne in vitro. Cela permettra donc au (à la) doctorant-e recruté-e d'acquérir des compétences pluridisciplinaires en vue d'un futur emploi de chercheur-se.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The development of resistance to antibiotics and antiparasitics is a real public health issue. According to the World Health Organization, multi-drug resistance currently concerns many bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii and enterobacteria involved in hospital-acquired infections. This resistance phenomenon is also found in parasites such as P. falciparum, the most virulent species of malaria. There is therefore an urgent need to develop effective new treatments targeting vital biological processes not targeted by current anti-infective agents, in order to avoid cross-resistance. One promising therapeutic approach involves blocking the function of enzymes that control membrane lipid metabolism, essential for cell integrity. FabZ and FabI, two essential enzymes involved in the biosynthesis of these lipids, are absent in humans but present in most bacteria and in P. falciparum. Thus, their selective inhibition offers the opportunity to develop a broad-spectrum antimicrobial with limited adverse effects. In this project, we will focus on the synthesis and study of FabZ and FabI inhibitors.
This work will be carried out jointly by five research teams. This multi-disciplinary collaboration in chemistry and biology should enable us, at the end of this project, to gather as much data as possible in order to rapidly propose a new drug candidate with a broad antimicrobial spectrum.
Most of the PhD student's work will be devoted to the synthesis and study of inhibitors of the target enzymes, and the in silico measurement of their physico-chemical properties. He/she will also be involved in cytotoxicity measurements and in vitro antibacterial evaluation. This will enable the PhD student to acquire multidisciplinary skills with a view to future employment as a researcher.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Début de la thèse : 01/10/2025
La plus grande partie du travail de thèse du (de la) doctorant-e visera à la synthèse et l'étude des inhibiteurs des enzymes visées et la mesure in silico de leurs propriétés physico-chimiques. Il (elle) interviendra également dans les mesures de cytotoxicité et l'évaluation antibactérienne in vitro. Cela permettra donc au (à la) doctorant-e recruté-e d'acquérir des compétences pluridisciplinaires en vue d'un futur emploi de chercheur-se.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The development of resistance to antibiotics and antiparasitics is a real public health issue. According to the World Health Organization, multi-drug resistance currently concerns many bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii and enterobacteria involved in hospital-acquired infections. This resistance phenomenon is also found in parasites such as P. falciparum, the most virulent species of malaria. There is therefore an urgent need to develop effective new treatments targeting vital biological processes not targeted by current anti-infective agents, in order to avoid cross-resistance. One promising therapeutic approach involves blocking the function of enzymes that control membrane lipid metabolism, essential for cell integrity. FabZ and FabI, two essential enzymes involved in the biosynthesis of these lipids, are absent in humans but present in most bacteria and in P. falciparum. Thus, their selective inhibition offers the opportunity to develop a broad-spectrum antimicrobial with limited adverse effects. In this project, we will focus on the synthesis and study of FabZ and FabI inhibitors.
This work will be carried out jointly by five research teams. This multi-disciplinary collaboration in chemistry and biology should enable us, at the end of this project, to gather as much data as possible in order to rapidly propose a new drug candidate with a broad antimicrobial spectrum.
Most of the PhD student's work will be devoted to the synthesis and study of inhibitors of the target enzymes, and the in silico measurement of their physico-chemical properties. He/she will also be involved in cytotoxicity measurements and in vitro antibacterial evaluation. This will enable the PhD student to acquire multidisciplinary skills with a view to future employment as a researcher.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Début de la thèse : 01/10/2025
Funding category
Public funding alone (i.e. government, region, European, international organization research grant)
Funding further details
Concours pour un contrat doctoral
Presentation of host institution and host laboratory
Université de Picardie - Jules Verne
Institution awarding doctoral degree
Université de Picardie - Jules Verne
Graduate school
585 Sciences, Technologie, Santé
Candidate's profile
Le candidat doit être ressortissant de l'UE. Le profil du candidat(e) recherché(e) est de type ingénieur chimiste ou universitaire avec un très bon dossier universitaire.
Le candidat de formation chimiste organicien, chimiste en chimie médicinale, pharmacien devra avoir une expérience en synthèse hétérocyclique et asymétrique. L'objectif de la thèse concerne la synthèse et l'étude de nouveaux antibiotiques. La personne recrutée devra être intéressée à travailler à l'interface de la chimie et de la biologie (chimie thérapeutique).
Candidates must be EU nationals. The profile of the candidate sought is that of a chemical engineer or university graduate with a very good academic record. Candidates with a background in organic chemistry, medicinal chemistry or pharmacy should have experience in heterocyclic and asymmetric synthesis. The aim of the thesis is to synthesize and study new antibiotics. The candidate should be interested in working at the interface between chemistry and biology (therapeutic chemistry).
Candidates must be EU nationals. The profile of the candidate sought is that of a chemical engineer or university graduate with a very good academic record. Candidates with a background in organic chemistry, medicinal chemistry or pharmacy should have experience in heterocyclic and asymmetric synthesis. The aim of the thesis is to synthesize and study new antibiotics. The candidate should be interested in working at the interface between chemistry and biology (therapeutic chemistry).
2025-04-30
Apply
Close
Vous avez déjà un compte ?
Nouvel utilisateur ?
More information about ABG?
Get ABG’s monthly newsletters including news, job offers, grants & fellowships and a selection of relevant events…
Discover our members
Nokia Bell Labs France
SUEZ
TotalEnergies
ASNR - Autorité de sûreté nucléaire et de radioprotection - Siège
Aérocentre, Pôle d'excellence régional
Institut Sup'biotech de Paris
MabDesign
CESI
Généthon
ANRT
MabDesign
CASDEN
Laboratoire National de Métrologie et d'Essais - LNE
Groupe AFNOR - Association française de normalisation
Ifremer
ADEME
ONERA - The French Aerospace Lab
Tecknowmetrix
PhDOOC
-
JobPermanentRef. ABG128969Institut Polytechnique des Sciences Avancées - IPSAToulouse - Occitanie - France
Enseignant-chercheur en Mécanique des fluides numérique
Open to all scientific expertisesAny -
JobPermanentRef. ABG129192Association Bernard Gregory (ABG)Paris (3ème) - Ile-de-France - France
Business Developer (F/H)
Open to all scientific expertisesAny